

# Chris Plummer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9161306/publications.pdf>

Version: 2024-02-01

39  
papers

1,551  
citations

516710

16  
h-index

330143

37  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2349  
citing authors

#	ARTICLE	IF	CITATIONS
1	British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Research and Practice, 2021, 8, G1-G18.	2.5	17
2	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 148, 76-91.	2.8	33
3	Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. European Journal of Cancer, 2021, 156, 127-137.	2.8	26
4	The European Society of Cardiology - A Digital Educator. Journal of European CME, 2021, 10, 2014039.	1.6	4
5	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the European Association of Cardio-Oncology Study Group of the European Heart Failure Association in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 2020, 22, 117-127.	7.1	364
6	Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. Lancet, The, 2020, 395, 492-493.	13.7	0
7	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. Europace, 2020, 22, 932-938.	1.7	8
8	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	2.8	11
9	Behind the scenes of the European Examination in General Cardiology. Heart, 2019, 105, 889-890.	2.9	8
10	How to succeed in the EEGC: a guide for trainees and their trainers. Heart, 2019, 105, 1044-1045.	2.9	5
11	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, The, 2019, 393, 2599-2612.	13.7	225
12	Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. British Journal of Cancer, 2019, 121, 109-116.	6.4	38
13	Chronic cardiovascular toxicity in the older oncology patient population. Journal of Geriatric Oncology, 2019, 10, 685-689.	1.0	7
14	Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer Journal, 2019, 9, 26.	6.2	71
15	Treatment specific toxicities: Hormones, antihormones, radiation therapy. Seminars in Oncology, 2019, 46, 414-420.	2.2	7
16	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients – who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	7.1	107
17	A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: The CRTee randomized crossover trial. Heart Rhythm, 2018, 15, 369-375.	0.7	25
18	Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 2016, 115, 1462-1470.	6.4	23

#	ARTICLE	IF	CITATIONS
19	National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded. <i>Europace</i> , 2015, 17, 339-342.	1.7	13
20	Unusual cause of hypoxemia after automatic implantable cardioverter-defibrillator leads extraction. <i>Annals of Cardiac Anaesthesia</i> , 2015, 18, 599.	0.6	3
21	Comparison of Sprint Fidelis and Riata defibrillator lead failure rates. <i>International Journal of Cardiology</i> , 2013, 168, 848-852.	1.7	21
22	Tunnelling defibrillator leads from the chest to the abdomen for chronic pain. <i>Europace</i> , 2013, 15, 844-844.	1.7	1
23	Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. <i>Journal of Clinical Oncology</i> , 2011, 29, e560-e562.	1.6	31
24	A survey of investigations performed prior to permanent pacemaker implantation. <i>Age and Ageing</i> , 2010, 39, 135-139.	1.6	2
25	Implantable cardioverter defibrillator therapy for non-ischaemic cardiomyopathy. What is the role of programmed electrical stimulation?. <i>Europace</i> , 2009, 11, 273-275.	1.7	2
26	Time to manual activation of implantable loop recorders--implications for programming recording period: a 10-year single-centre experience. <i>Europace</i> , 2009, 11, 1359-1361.	1.7	4
27	Inequity of access to implantable cardioverter defibrillator therapy in England: possible causes of geographical variation in implantation rates. <i>Europace</i> , 2009, 11, 1308-1312.	1.7	29
28	Delays and adverse clinical outcomes associated with unrecognized pacing indications. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 485-490.	0.5	12
29	Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. <i>Annals of Oncology</i> , 2009, 20, 816-827.	1.2	150
30	Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. <i>British Journal of Cancer</i> , 2009, 100, 684-692.	6.4	196
31	Sudden catastrophic pacemaker failure due to pacemaker generator malfunction: A rare but potentially fatal complication following permanent pacemaker implantation. <i>Resuscitation</i> , 2009, 80, 287-288.	3.0	0
32	The patient journey from symptom onset to pacemaker implantation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 955-960.	0.5	13
33	What's in the CARDS?. <i>Diabetic Medicine</i> , 2006, 23, 711-714.	2.3	2
34	The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. <i>Europace</i> , 2005, 7, 266-272.	1.7	17
35	Aortic regurgitation and Churg-Strauss syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 772-773.	0.5	4
36	Detection of Atrial Fibrillation by Permanent Pacemakers: Observations from the STOP AF Trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 333-340.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Implications of National Guidance for Implantable Cardioverter Defibrillation Implantation in the United Kingdom. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 479-482.	1.2	13
38	The use of permanent pacemakers in the detection of cardiac arrhythmias. Europace, 2001, 3, 229-232.	1.7	17
39	A continuous patient activity monitor: validation and relation to disability. Physiological Measurement, 1997, 18, 49-59.	2.1	27